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Abstract 
 
 One hundred and twenty sickle cell anaemia patients were studied 
between June and October 2006 to assess their growth and maturation and 
its relation to serum zinc level. They were randomly collected from 
referred clinic of Khartoum and Omdurman Teaching Hospitals. 
 They were studied by means of: 
1. Questionnaire. 
2.  Clinical examination. 
3.  Growth measurements. 
4.  Investigations. 
 The growth (weight and height) and sexual maturity (by Tanner 
staging) were assessed and compared by their serum zinc level. 
 The study revealed that weight is significantly affected and low 
weight for age is related to low serum zinc level (P < 0.05). In contrast to 
height for age and sexual maturity which were found not to be related to 
low serum zinc level. 
The severity of illness of the study group was assessed by number of 
hospital admissions, febrile and painful episodes, diarrhoeal diseases and 
number of blood transfusions. The nutritional status was assessed by the 
quantity and quality of food taken. 
The Medical care was assessed by history of vaccination and drug intake.  
 ﺧﻼﺻﺔ اﻻﻃﺮوﺣﺔ
  
ﻓﻲ ( ﺍﻟﻬﻼﻟﻴﺔ)ﺠﻠﻴﺔ ﻨ ﻤﺼﺎﺒﻴﻥ ﺒﺎﻻﻨﻴﻤﻴﺎﺀ ﺍﻟﻤﻼﹰ ﻁﻔﻤﺎﺌﺔ ﻭﻋﺸﺭﻭﻥ ﻰﺍﺸﺘﻤﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻋﻠ  
   .6002ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻭﻨﻴﻭ ﻭﺤﺘﻲ ﺍﻜﺘﻭﺒﺭ 
ﺭﻴﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺒﺎﻟﻌﻴﺎﺩﺍﺕ ﺍﻟﻤﺤﻭﻟﺔ ﻟﻼﻨﻴﻤﻴﺎ ﺍﻟﻤﺘﺠﻠﻴﺔ ﻓﻲ ﻜل ﻤﻥ ﻤﺴﺘﺸﻔﻲ ﺠﻌﻔﺭ ﺒﻥ ﺃﺠ  
  :ﺘﻴﺔ ﻵ ﺍﻟﺩﺭﺍﺴﺔ ﺒﺎﻟﻭﺴﺎﺌل ﺍﺴﺘﻜﻤﻠﺕﺃ ﻭﻗﺩ –ﻁﻔﺎل ﻸﻡ ﺩﺭﻤﺎﻥ ﻟﺃﻋﻭﻑ ﺍﻟﺘﻌﻠﻴﻤﻲ ﻭﻤﺴﺘﺸﻔﻲ 
  .ﺴﺘﺒﻴﺎﻥﺇ -1
 .ﻓﺤﺹ ﺴﺭﻴﺭﻱ -2
 .ﻗﻴﺎﺴﺎﺕ ﺒﺸﺭﻴﺔ -3
  ﻓﺤﻭﺼﺎﺕ ﻤﻌﻤﻠﻴﺔ -4
ﻭﻤﻌﺩل ( ﻭﺯﻥ ﻭﻁﻭل ﺒﺎﻟﻨﺴﺒﺔ ﻟﻠﻌﻤﺭ)ﻁﻔﺎل ﻷ ﻟﻬﺅﻻﺀ ﺍ ﺍﻟﻘﻴﺎﺴﺎﺕ ﺍﻟﺒﺸﺭﻴﺔﺘﻤﺕ ﺩﺭﺍﺴﺔ
  .ﺍﻟﻨﻤﻭ ﺍﻟﺠﻨﺴﻲ ﻟﺩﻴﻬﻡ ﻭﻤﻘﺎﺭﻨﺘﻪ ﺒﻤﻌﺩل ﺍﻟﺯﻨﻙ 
ﻨﻙ ﻟﺩﻴﻬﻡ ﺒﻤﻌﺩﻻﺕ ﺍﻟﺯﺎﹰ ﺘﺘﺄﺜﺭ ﺴﻠﺒ( ﺤﺴﺏ ﺍﻟﻌﻤﺭ)ﻁﻔﺎل ﻷﺍﻭﺯﺍﻥ ﺍﻥ ﺃﻭﻀﺤﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺃ
 ﻭﻤﻌﺩﻻﺕ ﺍﻟﺯﻨﻙ ﺠﻨﺴﻰﻁﻔﺎل ﻭﻨﻤﻭﻫﻡ ﺍﻟﻷﻁﻭﺍل ﺍﺃﻴﺠﺎﺩ ﻋﻼﻗﺔ ﺒﻴﻥ ﺇﻓﻲ ﺤﻴﻥ ﻓﺸﻠﺕ ﺍﻟﺩﺭﺍﺴﺔ ﻓﻲ 
  .ﻟﺩﻴﻬﻡ 
 ، ﺒﺎﻟﻤﺴﺘﺸﻔﻲ ﺘﻨﻭﻴﻬﻡﺴﺘﺒﻴﺎﻥ ﻋﻠﻲ ﻋﺩﺩ ﻤﺭﺍﺕ ﻹﺸﺘﻤل ﺍﺃﻟﻤﻌﺭﻓﺔ ﻤﺩﻱ ﺸﺩﺓ ﺍﻟﻤﺭﺽ ﻟﺩﻴﻬﻡ 
  .ﻻﻡ ﻭﻋﺩﺩ ﻤﺭﺍﺕ ﻨﻘل ﺍﻟﺩﻡ ﻟﺩﻴﻬﻡ ﻵ ﺤﺎﻻﺕ ﺍﺴﻬﺎﻻﺕ،ﻹ،ﺒﺎﺤﻤﻴﺎﺕ ﺒﺎﻟ ﺘﻨﻭﻴﻬﻡﻋﺩﺩ 
 ﺍﻟﺩﺭﺍﺴﺔ ﻋﻠﻲ ﻤﺩﻱ ﺍﻟﻤﺘﺎﺒﻌﺔ ﻭﺍﻟﻌﻨﺎﻴﺔ ﺒﻬﻡ ﻤﻥ ﺨﻼل ﻤﻌﺭﻓﺔ ﺼﺤﺔ ﺍﻟﺘﻁﻌﻴﻡ ﺸﺘﻤﻠﺕﺃﻜﻤﺎ 
  .ﺩﻭﻴﺔ ﺍﻟﻭﻗﺎﺌﻴﺔ ﻭﺍﻟﻔﻴﺘﺎﻤﻴﻨﺎﺕ ﻸﻭﺘﻨﺎﻭﻟﻬﻡ ﻟ
ﺤﺎﻭﻟﺕ ﺍﻟﺩﺭﺍﺴﺔ ﺍﻟﺘﻌﺭﻑ ﻋﻠﻲ ﺍﻟﺤﺎﻟﺔ ﺍﻟﻐﺫﺍﺌﻴﺔ ﻟﻬﻡ ﻤﻥ ﺨﻼل ﻤﻌﺭﻓﺔ ﻜﻤﻴﺔ ﻭﻨﻭﻉ ﺍﻟﻁﻌﺎﻡ  
  . ﺨﺎﺼﺔ ﺍﻻﻁﻌﻤﺔ ﺍﻟﻤﺤﺘﻭﻴﺔ ﻋﻠﻲ ﺍﻟﺯﻨﻙ ،ﺍﻟﻤﺘﻨﺎﻭل 
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Chapter One 
 
1. INTRODUCTION AND LITERATURE REVIEW  
 
Definitions: 
  Sickle cell disease (SCD):  Applies to all patients with 
at least at single HBS chain and one another abnormal β 
globulin. 
Sickle cell anemia (SCA):  is   a hemolytic anemia 
characterized by production of abnormal hemoglobin chain 
that tend to polymerize when deoxygenated causing distortion 
of RBCs morphology (sickling), with attendant vascular 
occlusion.  It results from inheritance of abnormal HB from 
both parents (homozygous state). 
 Sickle cell trait:  a carrier state (Hb AS) sickling occur on 
extremes of hypoxia and acidic PH(1). 
 
 
 
1.2 Historical Background: 
 2
The first published account of SCA was by Herrick in 
1910, who described the clinical hematological manifestation 
of the disease in a 20 years old medical student from 
Grenada(2). 
Pauling et al(3) determined that a point mutation in the 
gene coding the B chain of HB molecule. 
In 1977 Walter Gilbert and Fridrick Sanger working 
separately in US and England developed a new technique for 
DNA sequencing.  This lead to identification of mutations in B 
globulin chain gene. 
In 1984 a bone marrow translation in a child with 
leukemia and sickle cell anaemia produce a first reported cure 
of the disease. 
In 1995 hydroxyurea become the first and only drug 
proven to prevent complications of SCA. 
 
 
 
 
Sickle cell disease in Sudan: 
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 A study done in Sudan in Khartoum Teaching Hospital 
between 1996 and 2000, with 189 of SCD patients and 118 
controls.  They found that 93.7% belong to families of single 
ethnic descent. 
 The SCD was found to be predominant among the Afro-
asciatic groups (68.4%).  Those patients clustered in western 
Sudan (Kordofan and Darfor) from where 73% of all cases 
originate(4). 
SCD in the world: 
SCD is the most common single gene disorder in black 
Americans. 
SCA is prevalent in other ethnic groups as well, including 
those from Mediterranean area, Turkey and Indian 
subcontinent.  It may also be seen in people of Spanish 
descent and those from Caribbean, South and Central 
America(5,6). 
 
 
 
Pathophsiology of SCA: 
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 Biochemsitry of Hb: 
 The normal human Hb molecule consists of four globulin 
chain: tow α and tow β chains.  When α and β chains are 
normal this abbreviated Hb A. 
 Abnormal Hb is designated by the type of abnormality in 
the globulin chain; for example presence of one sickle β chain 
and one C β chain abbreviated Hb SC. 
 Homozygous SCD is designated Hb SS. 
 
Biochemistery of Hb S: 
 Hb S is formed when the amino acid valine is substituted 
for glutamic acid at the 6 position of β chain.  This single 
amino acid substitution has far-reaching effects on Hb 
interactions,  RBC morphology and hemodynamics.  Hbs β 
chain has an unusual propensity to bind with other Hb S 
chains when deoxygenated.  On to this basic polymer, other 
Hb molecule may also polymerize leading to a large polymer 
strands.  These rigid strands distort RBCs into a variety of 
elongated shape and decrease its deformability (7).  This sets 
the stage for vascular obstruction and hemolysis. 
 5
 Polymerization is an ongoing process and its extent 
depends on a number of factors; with the most important 
being extent of deoxygenation, Hb concentration in the cell, 
the intracellular composition of other Hb variants, PH and 
temperature. 
 Polymerization cause non-selective increase in membrane 
cations permeability with egress of water, RBCs dehydration 
and accelerate polymerization. 
 The end result of multiple episodes of polymerization and 
dehydration is dense irreversibly sickle cell, when oxygenated 
it may contain no polymer but distorted in shape and 
contribute to vaso-occulsion (7-9). 
 RBCs in SCA also appear to have an increased binding 
affinity for vascular endothelium.  It has been shown that 
adherent sickled RBCs inhibit vasorelaxation (10). 
 
 
 
Clinical Presentation of SCA and Management: 
Age and sex: 
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 Usually newborns has no features of SCA, but hemolytic 
anemia develop over the 3-4 months during replacement of Hb 
F by Hb S. 
Clinical features: 
Clinical features in SCA are mainly due to hemolytic 
anemia and vaso-occlusive components which is the most 
common and earliest manifestation of the disease.  Other 
problems in SCA include oestomylities, oestonecrosis, splenic 
infract and sequestration, acute chest syndrome, papillary 
kidney necrosis and renal insufficiency. 
Clinical features based on organ approach. 
The acute painful vaso-occlusive: 
The most common and earliest manifestation half of all 
SCA patients will experience pain by 4.9 years of age.  The 
pain is described as bone pain, but any organ may be 
involved.  It is caused by microvascular occlusion with 
subsequent tissue ischemia.  In young children it most 
commonly manifest as dactylitis. 
Management: 
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Dehydration and acidosis should be corrected, 
increasing oxygen tension, treating infection and control of 
pain by acetaminophen or if not responding by morphine. 
The lung: 
It is the most common site of involvement in SCA. 
Injuries range from acute processes such as pneumonia 
and acute chest syndrome to chronic entities such as 
pulmonary fibrosis. 
Pulmonary complications constitute the second cause of 
hospsitalization and now the leading cause of death(11). 
Pneumonia:  
It is estimated that children with SCA are 100 times 
more susceptible to develop pneumonia than other children, 
and they have 30% recurrence rate(12). 
Impaired immune status, a result of functional asplenia 
and other abnormalities in the immune system render patients 
with SCA prone to infections, mostly pneumonia(13). 
Pneumonia in SCA is most commonly caused by 
streptococcus pneumoniae, hemophilus influenzae, staph-
aureus, Chlamydia pneumoniae and salmonella (14). 
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Prevention:  is by oral penicillin prophylaxis begun by 
age 3 month and continued to at least 5 year of age (14). 
 
Acute chest syndrome (ACS): 
It is an acute pulmonary illness characterized by a new 
pulmonary consolidation, fever, chest pain and signs of 
distress.   
Causes are infection, fat emboli and bactermia which is 
more common in children than adult. 
Pulmonary vascular occlusion may lead to acute chest 
syndrome, and microvascular occlusion has been shown at 
thin section C.T. in ACS (15,16). 
Other factors linked to ACS include opoid use, 
pulmonary edema and parvovirus B19 (17). 
Treatment:  consist of hydration, transfusion, 
supplemental oxygen and analgesia.  Incentive inspirometry to 
improve atelectasis, antibiotic therapy for suspected infection 
and steroids may also be used (17). 
Chronic pulmonary disease (CPD) 
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CPD occur in about 4% of patients due to repeated 
episodes of pneumonia and acute chest syndrome (14). 
At histology CPD in SCA consists of pulmonary fibrosis, 
pleural scaring, adhesion and pulmonary arteriolar intimal 
hyperplasia with resultant pulmonary hypertension (17,18). 
In children with SCA, a marked increase in airway 
hyper-reactivity which is typically asymptomatic, has been 
shown in pulmonary function testing (73% of patients) (19).  
The skeletal system: 
The skeletal system of patients with SCA is remarkable 
for its life long preservation and frequent expansion of red 
(cellular) marrow, even in their epiphysis. 
Skeletal complications include infraction and 
oestomylitis.  Both of these problems are assumed to be 
caused by congested cellular marrow.  The cellular marrow 
impedes blood flow, enhances stasis, regional hypoxia and 
sickling and infract may result, these render the marrow 
susceptible to pathogens; oestomyelitis may result (20,21). 
Infraction: 
 10
Bone marrow infraction is thought to be the underlying 
cause of most pain crises in SCA. 
Patients with SCA are also prone to silent infraction, 
and the discovery of oestonecrosis may be incidental finding 
(22). 
In the spine, infraction appears as central square – 
shaped endplate depression, resulting from microvascular 
occlusion and subsequent over growth of the surrounding 
portion of endplate.  This appearance approximately seen in 
10% of patients, and it is pathogonomic of SCA and has been 
called H. shaped deformity. 
Epiphyseal infraction in SCA has predilection for 
proximal humeri and femora, although any bone may be 
involved. 
SCA is the most common cause of oestonecrosis of the 
hip in children and approximately half of patients will develop 
epiphseal oestonecrosis by the age of 35 (23). 
Treatment:   
Generally supportive with analgesics, hydration and 
antibiotics if infection is suspected. 
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When joint affected especially weight bearing joints, 
replacement may be necessary (24). 
 
Osteomylitis: 
It’s most common in the diaphyseal region of bone and 
most often found in the femur, tibia and humerus. 
Patients with osteomylitis present with pain, fever, 
erythma and elevated white blood count. 
The most common organisms are salmonella followed by 
staph-aures and gram negative bacilli. 
Although osteomylitis much less common than 
infraction, may be difficult to discriminate from infraction 
even with clinical, laboratory and radiological information. 
MR imaging is the prefer modality for evaluating marrow. 
 
 
 
The brain: 
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Stroke, atrophy and cognitive impairment are major 
consequences of SCA.  25% of all patients with SCA will have 
a neurologic complication over their life time. 
Many children will experience “silent infraction” (defined 
as absence of clinical symptoms with MR imaging findings of 
infract), it is twice as common as clinical infraction and may 
occur in up to 22% of children by 12 years of age. 
Other less common problems include intraparenchymal 
and subarachonoid hemorrhage and aneurysm. 
Infraction in patient with SCA is usually ischemic, 
embolic and thrombotic strokes are unusual (18,26).  
Infracts both silent and clinical are best detected by MR 
imaging. 
Infracts in patients with SCA tend to occur in the white 
matter and at the peripheral supply zones of middle and 
anterior cerebral arteries. 
Management: 
Because of life long cognitive and functional 
impairments that result from stroke, efforts directed toward 
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identifying patients at risk for stroke to institute preventive 
therapy. 
Transcranial Doppler ultrasound is a valuable tool for 
assessing large cerebral artery flow dynamics. 
Studies showed that elevated velocities in the distal 
internal carotid artery and middle cerebral artery correlate 
with increased risk of stroke (27,28). 
Although studies very slightly in the mean velocities that 
correlate with stroke, generally velocities greater 170-200 
cm/sec indicate increased risk. 
Preventive therapy, maintenance transfusion on monthly 
basis is now offered to these patients. 
Screening by transcranial Doppler ultrasound begins by the 
age of 3 years. 
Patients with two consecutive elevated velocities are 
offered maintenance transfusion therapy, with the goal of 
reducing Hb S concentration to 30% or less of total 
hemoglobin concentration. 
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Moya moya: 
 Reduced cerebral blood flow from any cause may result 
in development of fine collateral vascular channels.  These 
usually arise from thalamoperferate and lenticulosrriate 
arteries in response to occlusion of distal internal carotid 
artery.  This process is called moya moya for its angiographic 
appearance, such collaterals are seen in 35% or SCA patients 
at angiography (26,29). 
The liver: 
 The liver is frequently involved by SCA complications.  
Hepatitis is frequent, likely from repeated transfusions(33). 
 Intrahepatic bliary duct stones and cholestasis are also 
seen, which are hypothesized to be result from infraction(34).  
Pigmented gall stones are evident in up to 50% of adults and 
20% of children with SCA. 
 The liver may manifest changes of iron overload in 
transfusion dependant patient with SCA. 
The heart: 
Studies showed that cardiac changes in patients with 
SCA are electrical system fibrosis.  In some patients with 
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sudden death, dilated champers with septal hypertrophy, but 
normal contractility(35). 
The eyes: 
 Patients with SCA may experience acute retinal artery 
occlusion with sudden loss of vision in one eye:  this typically 
resolves in several days, although some long term visual 
impairment may result. 
 Orbital compression syndrome may result from infracts 
of osseous walls of orbit, which develop edema and 
subperiosreal hematomas(36). 
The ears: 
Large series report prevalence of hearing loss of 11 ? 
41% in SCD(37) the cochlear microvasculature in young may be 
susceptible to occlusion(38) and children should have 
audiometry after SCA crises to exclude readily manageable 
cause of educational handicap and preventable disability. 
Priapism: 
It is a prolonged painful erection of the penis that 
commonly occurs in children and adolescents with SCD.  It 
occurs in 2 form: stuttering episodes that last fewer then 4 
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hours but are often recurrent and may precede severe 
episodes; and severe episodes that last more than 4 hours and 
may eventually result in importance severe, episodes require 
urgent evaluation and treatment that may include hydration, 
analgesics, aspiration and irrigation by a urologist and some 
times blood transfusion(39). 
 
Neonatal Screening and Diagnosis: 
 Most infants with SCD are healthy at birth and become 
symptomatic later in infancy or childhood after fetal 
hemoglobin levels decrease.  Most infants with SCD born in 
United States are identified by routine neonatal screening(40,41).  
Screening can done by electrophoresis of fetal blood after 18 
week of pregnancy or by chorionic villous sampling from 9 
week of pregnancy or amniotic fluid sampling aspirated at 16 
weeks of pregnancy for SCD. 
 Confirmatory testing of infants with positive neonatal 
screening results and diagnosis of older patients who present 
with symptoms require hemoglobin separation by 
electrophoresis (cellulose acetate and cirate agar), isoelectric 
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focusing and/or high performance liquid chromatography 
(HPLC) (41). 
 
Health supervision for children with sickle cell 
disease: 
 The provision of comprehensive medical care decreases 
morbidity and mortality during childhood.  The provision of 
comprehensive care is a time – intensive endover that includes 
ongoing patients and family education, periodic 
comprehensive evaluation and other disease – specific health 
maintenance services, psychological care and genetic 
counseling. 
 
Family and patient education: 
 Identification of an infant with SCD through neonatal 
screening provides an opportunity to educate families before 
symptoms develop(40,41).  Initially the focus should include the 
genetics, basic pathophysiology of SCD and importance of 
regularly and scheduled health maintenance visits, penciling 
 18
prophylaxis and immunization.  Education about the need for 
urgent medical evaluation for treatment of febrile illnesses, 
acute chest syndrome, a plastic and sequestration crisis is 
critical. 
 Sequestration crises includes the need for medical 
attention immediately if the child is pale and listless, and 
instruction about abdominal palpation for determining spleen 
size. 
 Recognition and appropriate management of dectylitis 
and painful event should be reviewed.  As the child ages, other 
topics such as stroke, enuresis, priapism, cholelithasis 
delayed puberty, proliferative retinopathy, a vascular necrosis 
of hip and shoulder, and leg ulcers are introduced. 
 During middle childhood and adolescence, it includes 
genetic basis and issues related to contraception, carrier of 
partners, genetic counseling and prenatal diagnosis. 
 The ultimate goal is to enable families to cope with the 
child’s complex chronic illness and enhance the child’s 
potential for successful transition to adulthood. 
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Health maintaince: 
 In addition to ensuring compliance with 
“recommendations for preventive pediatric health care” of 
American Academy of Pediatrics (AAP), the following SCD 
related issues should be addressed periodically(42): 
 
Prophylactic medications: 
 All infants with Hb SS receive penicillin prophylaxis, 125 
mg, and twice daily initiated by 2 months of age(40).  The dose 
is increased to 250 mg orally, by 3 years of age and continued 
at least until the 5th birth day(45).  Erythromycin is used in 
children with proven penicillin allergy. 
 
Immunization: 
 Timely administration of routine immunizations 
recommended by the AAD is essential(47).  Children with SCD 
should receive 7-valent pneumococcal conjugate and 23-valent 
pnuemococcal polysaccharide vaccines.  Yearly influenza 
immunization is recommended. 
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Comprehensive medical evaluations: 
 All patients should have regularly scheduled 
comprehensive medical evaluations to review previous disease 
manifestation, document important baseline physical findings 
and laboratory, values, monitor growth and development, 
detect early signs of chronic organ damage and develop 
individualized patient care plans(41). 
 The clinical course of each patient with SCD should be 
regularly reviewed by pediatric hematologist.  Oncologist 
generally at the time of comprehensive evaluations, the 
possibilities of chronic transfusions, hydroxyurea, and stem 
cell transplantation should be considered. 
Acute illness: 
 Is characterized by relatively common childhood signs 
and symptoms, such as fever, cough, abdominal pain, pallor 
and limping, can rapidly become life threatening.  
Unfortunately, delayed or inadequate evaluation and 
treatment of acute illness remains an important cause of 
preventable morbidity and mortality(48).  The goal of ensuring 
timely medical treatment for acute illness also is facilitated by 
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providing anticipatory guidance to patients and families about 
early recognition, appropriate medical evaluation and 
treatment of common acute complications(40,41). 
 
Growth and Development in SCA patients.    
Sickle cell anemia is a severe congenital and chronic 
illness, which, even today shows critical rates of morbidity and 
mortality(49).  About 25% of children with this disease have 
satural deficit and retarded skeletal maturation and pubertal 
development(50).  Besides anemia and peripheral tissue hypoxia 
and growth hormone deficiency (GH) and starvation also 
reported in SCD, factors well known to have a negative 
influence on growth. 
The mean heights and weights of SCD children are within 
normal parameters at birth, but fall below those of normal 
children by 1-2 years of age(51).   
Platt et al(49) reported across sectional analysis of growth 
data in 2115 patients with sickle cell hemoglobinopathies (age 
2 to 25 years) participating in the co-operative study of SSD 
and showed that patients with SS and SB were consistently 
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shorter and weighted less than normal controls and patients 
with SC and SB+.  These differences increased with age so that 
the greatest degree of growth failure was observed in 
adolescents(52). 
Henderson et al(53) in a study of 63 patients with SCA 
found that 25% had impaired growth (< 5th percentile for 
height, weight or weight/height).  Among the adolescents 46% 
had poor growth.  Similar findings have been reported in other 
cross-sectional and longitudinal studies(54). The 
pathophysiology of growth failure in a SCD is poorly 
understood.  The cooperative study of SCD data did not 
detected the effect of socio-economic status on growth; 
however other studies have suggested that nutritional and 
other micronutrients factors such as zinc may play a role in 
growth failure(53).   
One study showed an improvement in both growth 
parameters and the clinical course following caloric 
supplementation.  A variety of micronutrients deficiencies have 
been suggested in SCD.  Numerous case reports describing an 
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exacerbation of the chronic anemia that was reversed by folic 
acid therapy led to routine folic acid supplementation(55). 
One study done by Heyman MB and his colleagues report 
gain in height and weight in two children with SCD given a 
high caloric nutritional supplement by naso gastric feeding(56).  
However most studies and growth retarded children with SCD 
have shown adequate caloric and nutritional intake, indicating 
growth retardation can not be explained by nutritional factors 
alone in most patients(57). 
The influence of sickle cell hemoglobinopathies on growth 
and development, including the height, weight and sexual 
maturation of 2115 patients aged 2 ? 25 years old who had 
homozygous SCD SS, SC disease, sickle beta thalasaemia was 
studied.  Using regression analysis of these and maturation 
curves for each hemoglobinopathy, it was found that all 
hemoglobinopathy groups were found significantly different 
from published normal, and that subjects with SS were 
consistently smaller and less sexually developed than others 
(52). 
 24
The relationship of growth with hemoglobin and fetal 
hemoglobin showed potentially interesting gender differences, 
high hemoglobin and fetal hemoglobin concentration being 
related to attained height and weight at 5 and 7 years and to 
height increment from 3-9 years in boys not in girls.  Gender 
differences were only significant for the relationship between 
hemoglobin and weight and weight/height.  Further analysis 
suggested that the apparent effect of total hemoglobin on 
height and weight was mediated through an effect of fetal 
hemoglobin.  Gender differences in anthropometric indices 
and in nutrient intake were also confined to males in a 
Nigerian study (58).  
 
Zinc Deficiency and Supplementation in Children: 
 Zinc is an essential trace element.  It is intake is closely 
related to protein intake; as a result, it is an important 
component of nutritionally related morbidity worldwide. 
The usual oral intake is approximately 4 – 14 mg/day 
and dietary.   Sources include animal products such as meat, 
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sea food and milk.  Ready to eat cereals contains the greatest 
amount of zinc from plant product (59). 
Lacto Vegetarians need more milk, eggs, grains, nuts and 
seeds to increase requirement. 
Zinc circulates at concentration of 70 ? 120 microg/dl.  
It is an important internisic metal component or activating 
cofactor for more than 70 important enzyme systems, 
including carbonic anhydrase, alkaline phosphatases, 
dehdyrogenases and carboxy peptidases.  It is involved in 
regulation of nucleoproteins and activity of various 
inflammatory cells and plays a role in growth, tissue repair 
and wound healing, carbohydrate tolerance and synthesis of 
testicular hormones. 
10 to 40% of dietary zinc is absorbed in the small 
intestine; absorption is inhibited by the presence of fiber and 
phytates in the diet that binds to zinc as well as dietary iron 
and cadmium. 
Zinc deficiency:   
It is important problem in children and adolescents 
particularly in developing countries.  The true incidence of 
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zinc deficiency is not known because of non specificity of 
symptoms and imprecise diagnostic methods. 
Symptoms attributed to severe zinc depletion include 
growth failure, primary hypogonadism, skin disease, impaired 
taste and smell, impaired immunity and resistance to 
infection. 
Zinc supplementation in populations likely at risk for 
zinc deficiency appears to have beneficial effects on incidence 
and outcome of serious childhood infectious diseases. 
Zinc deficiency occurs in breast fed babies – especially 
preterm whose mothers have low zinc, in hereditary zinc 
malabsorption (acrodemitis enteropathica), Crhon disease, 
liver and renal diseases and sickle cell disease. 
Zinc depletion in sicklers appear to reflect increased 
urinary excretion caused by a renal tubular defect and 
perhaps chronic hemolysis or impaired absorption, not in 
adequate dietary intake (60). 
Diagnosis: Zinc status can be assessed by measurement 
of zinc in blasma, erythrocytes, neutrophils, lymphocytes and 
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hair.  A low blasma zinc is usually defined as a less of 60 
microg/dl (61). 
 
Zinc Supplementation:   
Zinc deficiency is associated with impaired immunity and 
propensity to infections, is said to be common in children in 
developing countries in which children experience high rates 
of serious infections.  Zinc supplementation has been 
evaluated both as a therapeutic and as a potential 
prophylactic agent in children in these populations (62). 
Several randomized studies have shown that zinc 
supplementation reduces the duration and severity of acute 
diarrhea in children who are likely to be zinc deficient (61). 
Numerous studies in multiple underdeveloped countries 
have shown a preventive effect of oral routine zinc 
supplementation on the incidence of diarrheal diseases and 
pneumonia (62,63). 
Some studies have described improved linear growth in 
infants who received zinc supplementation, especially in those 
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who were stunted or had low plasma zinc concentrations at 
base line (64). 
A meta-analysis study confirmed the effect of zinc 
supplementation in enhancing linear growth velocity and 
weight gain in children with growth retardation (65).  Because 
zinc has no pharmacological effect on growth, a growth 
response to zinc is taken as evidence of a preceding growth-
limiting zinc deficiency(66). 
Zinc supplementation has improved linear growth in 
otherwise healthy non-SCD children with mild growth failure 
(67,68).   
Zinc supplementation has improved linear growth in 
otherwise healthy, non-SCD children with mild growth failure 
in North America (67).  Guatemala (68),  Chile (69),  Ecuador (70) 
and Ethiopia (71). 
A recent meta analysis study of 25 Zinc supplementation 
trials conducted in children between 1969 and 1996 (72) 
showed a small but significant improvement in height 
(0.22SD) with zinc supplementation (P < 0.0001), especially in 
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those children with the greatest degree of stunning (-2 SD) and 
lowest baseline plasma zinc concentrations. 
 
Zinc Status in SCD patients: 
It has been recognized for several decades that children 
with SCD especially those with SCD. SS has poor growth and 
delayed maturation (73). 
Increased nutritional requirements, poor nutritional 
status or both have been documented in children with SCD 
(74,75). 
Zinc deficiency has been suggested as a contributing 
factor to growth failure in SCD on the basis of case reports 
and cross-sectional studies (75,76).  In a large cross-sectional 
survey of plasma zinc status in children with SCD-SS, low 
growth status, low fat-free mass and delayed skeletal were 
associated with low plasma zinc concentrations (75). 
In adults with SCD given Zinc supplements, improved 
immune function (fewer illnesses and increased natural killer 
cell activity) and red blood cell integrity (reduced number of 
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irreversibly sickle cells and increased RBC survival) were also 
observed (77,78). 
The etiology of zinc deficiency in SCD is not known.  
Possible mechanisms include increased requirements 
secondary to erythrocyte hemolysis, chronic inflammation, 
increased protein turnover and urinary zinc losses, inadequate 
zinc intake because of poor diet, and inadequate net intestinal 
absorption.  Possible zinc deficiency is suggested by poor 
growth and delayed skeletal and sexual maturation commonly 
observed in children with SCD (73,79). 
At birth infant with SCD-SS are normal in size, but 
significant growth deficits become apparent by 5 year of age 
(80). 
In recent study survey of 36 children with SCD in 
Baltimore, 25% had height, weight and weight for height 
values were less than the 5th percentile of the NCHS standards 
(81). 
A study done on the effect of zinc supplementation on 
growth and body composition in children with SCD in 
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children’s hospital of Philadelphia Nutrition Center, General 
Clinical Research Center and the comprehensive sickle center.   
It showed that an improved in linear growth in 
prepubertal children with SCD-SS whose diets were 
supplemented with 10 mg elemental zinc per day as zinc 
sulphate in randomized, placebo-controlled study(73).   
In one study, for example, 44% of 104 children with SCD 
had low plasma zinc concentrations (57).  These children, when 
compared to those with normal plasma zinc levels, had 
significant reduction in height, weight, upper arm muscle 
area, and in older children delayed sexual maturation.  
Whether zinc deficiency promotes infection in children with 
SCD remains controversial(77). 
Although the etiology of mild zinc deficiency in SCD is 
unknown, the significant declines in height for age and weight 
for age Z-scores observed in the control group, which are 
typical of the gradual growth failure that occurs in children 
with SCD, suggest that children with SCD are unable to meet 
their zinc requirements through diet. 
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A study conducted by Olivera et al (82) revealed zinc levels 
are low in children with SCD in comparison to normal children 
without SCD.  However there was no difference in zinc levels in 
children with or without growth failure, suggesting other 
metabolic disturbances are involved.  However most studies of 
growth retardation have shown adequate nutritional and 
caloric intake, indicating that growth retardation can not be 
explained by nutritional factors alone in most patients. 
Inadequate zinc intake is another possible mechanism of 
zinc malnutrition in SCD.  Poor appetite is frequently reported 
by care providers of children with SCD, and anorexia 
associated with painful or febrile episodes is common (83). 
However the few studies of nutrients intake in children with 
SCD are based on small sample sizes (84) and therefore have 
limited generalizability in a comparison of 9 children with SCD 
and control subjects, lower RBC zinc was not associated with 
differences in zinc intake (84) , similarly Phebus et al (85) 
documented lower serum zinc concentrations in 80 children 
with SCD than in 44 healthy control subject aged 3 to 18 and 
found no significant differences in dietary zinc intake. 
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A small randomized trial of zinc supplementation in 10 
male subject aged 14-17 years with SCD and growth 
retardation showed significantly improved growth and skeletal 
maturation over 1 year(86). 
In the literature, reports showing zinc deficiency in SCD 
did not separate groups by stature and compared individuals 
with a large age gap and at different stages of sexual 
development(87,88).  This reinforces the fact that there is no 
unifocal relationship between zinc and growth in patients with 
SCD, although they frequently present low serum levels.  This 
strongly suggest that zinc does have some influence, but 
implies the existence of additional factors. 
Although several studies did not succeed in relating low 
s. zinc level in SCD with nutritional status(84,89),  we can not 
rule out any interference of malnutrition in the zinc results 
and also as a cause of short stature.  Probably in the presence 
of chronic and severe disease as SCA, conditions of 
malnutrition and mild nutritional deficiencies are often 
difficult to establish by clinical or laboratory data. 
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In 1994 Ilham M. Omer studied the physical growth and 
school performance among SCA patients.  She found that the 
weight and height is significantly lower than the control group 
within all age group. 
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? Justification and Objectives 
 
? Sickle cell disease is a common chronic problem in 
Sudan affecting significant number of children. 
? Children with SCD have poor growth and delayed 
maturation, which may be partially due to zinc 
deficiency. 
? Poor growth and delayed maturation in children with 
SCD-SS may be improved with adequate nutritional care, 
particularly zinc supplementation. 
 
 
Objectives: 
 
? To measure zinc level in patients with SCA. 
? To evaluate the relation between zinc level, linear growth 
and sexual maturation of patients with SCA. 
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Chapter Two 
2-  MATERIALS AND METHODS 
 
3.1 Study Design: 
Is a cross-sectional hospital based case control study. 
3.2 Selection of Cases: 
Study Population: 
The study was done for SCA patients who presented to 
Gafar Ibn Oaf Hospital and Omdurman SCA referred clinic 
from June to October 2006. patients are selected randomly 
from those attending the referred clinic. 
Inclusion Criteria: 
120 patients were included in the study.  Their age 
ranged from one to seventeen years, who are proved sickler by 
hemoglobin electrophoresis. 
Exclusion Criteria: 
Patients excluded from the study those who are known to 
have chronic medical problem other than SCD as 
malabsorption (inflammatory bowel disease, intestinal by pass 
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surgery and nephrotic syndrome).  Also patients on 
hydroxyurea or supplements containing zinc or those who 
refused to participate were  excluded from the study. 
Verbal consent was taken from all parents or 
accompanying care takers of children with SCA, and from 
physicians caring for them especially before taking blood 
sample. 
3.3 Study Design: 
A control group in the study are sickler patients whom 
were zinc levels are normal and compared to those with low 
zinc levels. 
Zinc levels of cases and control group were compared to 
anthropometric measurements and sexual maturation in older 
age group (> 9years old). 
3.4 Data Collection: 
A questionnaire was completed for all cases.  Answers 
were taking from accompanying care takers or the child 
himself. 
The questionnaire consists of:   
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3.4.1 Clinical history: 
Personal history including full name, age, sex, residence 
and tribe. 
Age at diagnosis of disease. (for how long patient is 
known sickler). 
PH of hospital admissions by febrile illnesses, diarrhoeal 
diseases, painful crises or blood transfusions. 
Nutritional history including amount (number of meals 
per day), quantity (particularly meat, milk, sea food), to 
determine adequacy of nutrition. 
Social history was taken about the income, housing 
condition (number of room, kitchen, latrines and a availability 
of safe water supply and electricity, and number of family 
members. 
Vaccination history was taken and patients were either 
completely, partially or not vaccinated at all. 
Family history of consanguinity, similar problem or 
deaths. 
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Drug history including folic acid, prophylactic antibiotic 
or other drugs was also taken. 
3.4.2 Clinical examination: 
All patients were examined generally for pallor, fever, 
jaundice, respiratory and cardiovascular examination and 
signs of art failure. 
Abdominal examination for organomegaly. 
Searching for leg ulcers, oestomylites and hemiplegia. 
 
Anthropometric measurements: 
Weight:  Patient were weighted with light clothes 
and without shoes ( to within 0.1 kg) and weight was 
expressed in z-scores and compared to international NCHS 
standards. 
Height:  height is taken to all patients without 
shoes and child standing with heels and back in contact with 
height stadiometer (to within 0.1 cm) and expressed in z-
scores and compared to international NCHS standards. 
Assesment of Maturation: 
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 Any patient > 9-years and < 18 year was assessed for 
sexual maturity in a private room; genital and pubic hair for 
males and breast and pubic hair for females compared to the 
drawings of Tanner stages.  
? Tanner stages for males are as follow: 
o Stage I: is preadolescent; tests, scrotum and 
penis about the same size as in early childhood. 
o Stage II: .  Enlargement of scortum and tests and 
reddening and change of texture of scarcel skin.   
Little or no enlargement of penis (10.5 to 12.5 
years). 
o Stage III: Enlargement of penis mainly in length, 
further growth of tests and scrotum (11.5 to 14 
years). 
o Stage IV:   Increased size of penis development of 
glans, further enlargement of tests and scortum and 
darkening of scrotal skin. 
o Stage V:   Gentilia of adult size and shape (14 years 
to adult). 
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Tanner stages for females: 
Stage I: Preadolescents.  No breast budding .  
Stage II:   Continued enlargement of breast.   
Stage IV: Areola and papilla from 2ndry mound.   Stage 
V: Mature female breast.  
3.5    Investigation: 
Two ml of blood is taken from every patient with SCA in a 
plane tube and plasma is separated into glass and stored at 
20 oC.  serum can be used within 24 hours. 
Serum plasma zinc was measured chemically by 
spectrophotometry (zinc present in the sample is deleted by 5-
Br-PAPS (5-bromo-2 pyridyiazo) -5- (N. propyl-N-
sulphopropylamino)-phenol in the reagent. 
The formation of this complex is measured at a wave 
length of 560 nm.  The measurement must be done within 60 
minutes when serum mixed with reagent. 
Serum zinc level is measured in µmol/L and the normal 
range is between 9.8 – 16.8. 
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3.6     Research Team: 
- The researcher himself 
- Lab technician. 
3.7 Statistical Analysis: 
   The questionnaire was coded, and a master sheet was 
constructed to arrange the raw data.  The tables were then 
drown and description statistics measured. 
Data were entered into statistical package for social 
science (SPSS); computer programme for analysis.  The growth 
parameters (weight and height for age), serum zinc level were 
performed with chi-square test. Level of significance was set at 
p value < 0.05. 
EPI info 2002 statistical package computer programme 
was used to determine the nutritional status of children(90) .  
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Chapter Three 
 
3-  Results 
 
 
3.1 Age and Sex of Patients with SCA included in 
the Study: 
Table 1: shows that 46.7% of total numbers are males 
while the remaining 54.3% are female. 
Table  2:  shows that 50 patients are below 5 years of 
age (about 33%) and 48 patients are above 8 years old (40%). 
3.2 The Tribes of Cases Involved in the Study: 
It shows that almost all patients are from tribes 
belonging to western Sudan, while only 2 patients (1.7%) are 
belonging to Alzandi tribe. 
The large number of patients are from Messeryia and 
Bargo tribe. (Table 3). 
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Table 1:  Distribution according to sex of patient 
involved in the study group 
 
Sex Frequency Percentage 
(%) 
Male 56 46.7 
Female 64 53.3 
Total 120 100.0 
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Table 2:  Distribution of patients according to age 
 
Age 
(Years) 
Frequency Percentage 
(%) 
1 – 2 11 9.2 
2.1 – 4 29 42.2 
4.1 – 8 32 26.7 
9 – 17 48 40 
Total 120 100.0 
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Table 3:  Distribution of patients according to 
tribes 
 
Tribe Frequency Percentage 
(%) 
Messerya 24 20 
Bargo 22 18.3 
Foor 10 8.3 
Hawsa 9 7.5 
Tama 12 10 
Zandi 2 1.7 
Others (Falata, 
Gawama, Barno, 
Dago, Rizigat) 
41 34.2 
Total 120 100.0 
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3.3 Age of Patients at Time of Diagnosis: 
Table 4:  shows that (30.8%) are diagnosed at 4 month 
of age, while (45.8%) are diagnosed before 1 year of age.  That 
means most of patients (76.6%) are diagnosed early (before 1 
year), but (12.6% are diagnosed late after (5 years of age). 
3.4 Number of Previous Hospital Admissions: 
Table 5 shows that of 120 patients only 11 are not 
admitted at all, while 50.8% are admitted less than 5 times 
and 27.5% are admitted frequently (more than 9 times). 
3.5 Number of Blood Transfusions Given to the 
Patients: 
Table 6 shows that 25.8% are not transfused at all while 
15.8% patients are transfused more than 5 times. 
3.6 Number of Hospital Admissions by Febrile 
Illnesses: 
Table 7 shows that only 10% of cases did not develop 
febrile illness that necessitate hospital admission.  All the rest 
of patients are admitted by febrile illness and (27.5%) are 
admitted more than 8 times. 
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Table 4:  Age of patients at diagnosis 
 
Age 
  
Frequency Percentage 
(%) 
0 – 4 months 37 30.8 
5 months – 1 year 55 45.8 
1.1 – 5 years 13 10.8 
> 5 years 15 12.6 
Total 120 100.0 
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Table 5:  Number of previous hospital admissions 
 
Admissions Frequency Percentage 
(%) 
No admission 11 9.2 
1 – 5  61 50.8 
6 – 9 15 12.5 
> 9   33 27.5 
Total 120 100.0 
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Table 6:  Number of blood transfusions given to the 
SCA patients 
 
Transfusion Frequency Percentage 
(%) 
No of transfusion 31 25.8 
1 – 2 45 37.6 
3 – 5 25 20.8 
> 5 19 15.8 
Total 120 100.0 
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Table 7:  Hospital admission by febrile illnesses 
 
Febrile illnesses 
(attack) 
Frequency Percentage 
(%) 
No attack 12 10 
1 - 2 18 15 
3 – 5 44 36.7 
6 – 8 13 10.8 
> 8 33 27.5 
Total 120 100.0 
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3.7 Hospital Admissions by Diarrhoeal Diseases: 
Figure 1: shows that diarrhoeal diseases are not a 
common presentations.  75% are not admitted at all by 
diarrhea and only 10% of patients are admitted by diarrhoeal 
more than 5 times. 
3.8 Admission by Hand Foot Syndrome: 
Table 8: shows that only 24% are not admitted before by 
this problem and 34.2% are admitted more than 5 times by 
hand foot syndrome. 
3.9 Nutritional Status in Children included in the 
Study: 
Figure 2: shows that the majority of patients has 
adequate nutritional status (65.2%).  (34.8%) had poor 
nutritional status. 
3.10 Consanguinity Among Patients with SCA: 
Table 9:  shows that a considerable number are a 
product of consanguineous marriage (68.3%) while only 31.7% 
are not a product of consanguineous marriage. 
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Figure 1: Sex of the study group with SCA
n = 120
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Figure 2: Distribution of the study group according to tribes
n = 120
Messerya Bargo Foor Hawsa Tama Zandi Others 
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Figure (3): Hospital admissions by diarrhoeal disease 
n = 120
75%
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No attack 1-5 attack > 5
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Figure (4): Nutritional status among SCA patients
n = 120
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Figure (5):  Social Class of SCD
n = 120
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Figure (6): Height for age in SCA patients
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Figure (7): Weight for age in SCA patients included in the study
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Table 8: Hospital admission by hand foot 
syndrome 
 
Hand foot 
syndrome 
(times)  
Frequency Percentage 
(%) 
No attack 29 24.2 
1 – 3 50 41.6 
> 3  41 34.2 
Total 120 100.0 
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Table 9:  Family history of consanguinity 
 
 Family history Frequency Percentage 
(%) 
Yes 82 68.3 
No 38 31.7 
Total 120 100.0 
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3.11 Family History of Similar Problem and Death: 
Table 10and 11: shows that (35.8%) of patients had 
similar problem in their families, while (18.3%) showed a 
history of death by similar problem. 
3.12 Vaccination among Children Included in the 
Study: 
Table 12: shows that almost all of children completed 
their recommended vaccination (98%).  Only one patient are 
not vaccinated at all and another one patient partially 
vaccinated. 
3.13 Drug History of Patient: 
Table 13: shows that (98.3%) of patients are taking folic 
acid, while only (20%) of patients are taking prophylactic 
antibiotic although (40%) of patients are below 5 years of age. 
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Table 10:   Family history of similar problems 
 
 Similar problems Frequency Percentage 
(%) 
Yes 43 35.8 
No 77 64.2 
Total 120 100.0 
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Table 11:  Family history of death by a similar 
problem 
 
 Family history Number Percentage 
(%) 
Yes 22 18.3 
No 98 81.7 
Total 120 100.0 
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Table 12:  vaccination among cases included in the 
study 
 
Vaccination history Number Percentage 
(%) 
Not vaccinated 1 0.85 
Partially vaccinated 1 0.85 
Vaccinated up to age 118 98.3 
Total 120 100.0 
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Table 13:  Drug history of the sickler 
 
 Drug history Number Percentage 
(%) 
Folic acid 118 98.3 
Prophylactic antibiotic 20 17 
Other drugs 13 10.8 
Total 120 100.0 
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3.14 Social Class of SCA Patients Included in the 
study: 
Figure 3: shows that most of patients are of low socio-
economic class (71.7%) while only two patients (1.7%) are of 
high class. 
3.15 Clinical Presentation of SCA Patients at Time 
Attending the Referred Clinic: 
Table 14: shows that most of patients are pale (83.3%) 
and having jaundice (55.8%).  27.5% of patients are presented 
in painful crises and only (6.7%) have or had a history of 
oestomylities. 
2.5% develop CVA and hemiplegia. 
3.16  Figure 4: shows the growth parameters for SCA 
patient.  It shows that weight is more affected than height, 
(3.3%) of patients their height is severely affected, while 
(12.5%) of patients their height is moderate for age the 
remaining 101 patients (84.2%) were within normal for age (- 
1.99 SD up to the SD). 
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Table 14:  Clinic presentation of patients at time of 
attending referred clinic 
 
 Clinical 
presentation 
Frequency Percentage 
(%) 
Pallor 100 83.3 
Jaundice 67 55.8 
Fever 26 21.7 
Hand foot syndrome 14 11.7 
Abdominal pain 15 12.5 
Chest pain 4 3.3 
Hepatomegaly 48 40 
Splenomegaly 22 18.3 
Oestomycities 8 6.7 
Hemiplegia 3 2.5 
Heart failure 0 0 
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Figure 5: shows weight for age and were 9 (7.5%) 
patients are their weight are > - 3 SD for age, while 43 patients 
their weight is -2.99 SD to -2 SD.  The remaining 68 patients 
were normal for age -1.99 SD to +ve SD. 
3.17  Table 15: shows Tanner stages of 48 patients whom 
were ages between 9 ? 17 years; it shows that only 12 (25%) 
had normal tanner stage, while the remaining 36 paptients 
(75%) had delayed tanner stage for age. 
3.18 Table 16: shows s-zinc level of the 120 patients and 
only 36 patients their zinc level is low (< 9.8 micromol/L) while 
the remaining 84 patients their zinc level is within normal. 
3.19 Table 17:  shows the relation between zinc level and 
height for age of the patients, and the results are; 4 patients 
with low zinc level are moderately short for age and 32 
patients with low zinc level are within normal height for age.  It 
shows that there is no significant relation between zinc and 
height. 
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Table 15:  Tanner stages of the 48 patients of SCA 
(ages between 9 ? 17 years 
 
Tanner stage Number Percentage 
(%) 
Normal Tanner stage 12 25 
Delayed Tanner stage 
for age 
36 75 
Total 120 100.0 
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Table 16:  S. zinc level in SCA patients included in 
the study 
 
Result of blood 
sample 
Number Percentage 
(%) 
Normal s. zinc > 9.8 
µmol/L 
84 70 
Low s. zinc level < 9.8 
µmol/L 
36 30 
Total 120 100.0 
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Table 17:  Height for age of sickle patients versus 
serum zinc level  
 
Result of 
blood sample 
Severe 
(> - 3 SD) 
Moderate 
(-2.99 SD ? - 
2 SD 
Mild 
( < 1.99 SD) 
 
Low s. zinc 0 4 32 
Normal s. zinc 4 11 61 
 
P = 0.441 
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3.20 Table 18:  shows the relation between zinc level and 
weight for age of the 120 patients and results are; 2 patients of 
severely low weight for age (> -35D) had low s-zinc level.  20 
patients of moderate low weight for age (-2.99 SD to -2 SD) 
had low s. zinc level, and 14 patients with normal weight for 
age their zinc level is low. 
This shows that there is a significant relation between 
weight and height. 
3.21  Table 19:  shows the relation between zinc level and 
sexual maturation. 
 This table shows that 14 patients with delayed tanner 
stage have low serum zinc level while 22 patients with delayed 
tanner stage have normal zinc level.  The p value of the test 
0.157 indicating no significant relation between sexual 
maturity and zinc level. 
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Table 18:  weight for age versus s. zinc level 
 
Result of 
blood sample 
Severe 
(> - 3 SD) 
Moderate 
(-2.99 SD ? - 
2 SD 
Mild 
( -1.99 SD) 
 
Low s. zinc 2 20 19 
Normal s. zinc 7 23 54 
 
 
P = 0.032 
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Table 19:  Tanner stage versus serum zinc level 
 
Zinc level Tanner stage 
 Normal delayed 
Normal 10 22 
Low 2 14 
Total 12 36 
 
 
P  = 0.157 
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Chapter Four 
 
4- DISCUSSION 
 
 
 This is conducted among sickle cell anemia children in 
Khartoum State.  Sickle cell anemia is one of the commonest 
inherited disorder affect children especially of western ethenic 
descent.  It studied the relation between growth parameter 
(height and weight for age), sexual maturity and their serum 
zinc level. 
 The age group involved is between 1 and 17 years about 
two third of them are below 5 years and the other one third is 
above 5 years of age.  The sex of patients in the study is nearly 
canal, but the differences in sex are not an objective.  However 
their age was considered, because sexual maturity is one of 
the objective of the study. 
 Almost all of the patients are from tribes of western 
Sudan and this because the consangious marriage is still a 
problem need to be discussed in detail with these families of 
inherited disorder. 
 77
 Wethers DL from Colombia University, studied the effect 
of sickle cell anaemia on growth and sexual maturation.  He 
found delayed growth at all ages and in both sexes and 
demonstrated delay is sexual maturation in SCA children(91).  
He studied only the growth and maturation and not relate it to 
serum zinc level. 
 The study showed that there is a significant relation 
between reduction of weight for age and low serum zinc level 
(P < 0.05), compared to sicklers with normal serum zinc level.  
Similar results was obtained by University of Lorin, Nigeria, 
which found an anthropometric values were lower than the 
50th percentile for SCA children.  Of all parameters weight for 
age was particularly deficient(92).  However this study did not 
relate growth parameters to serum zinc level. 
 This result is also similar to the study done by Zamel BS, 
Stalling VA and their colleagues, university of Pennyslvania, 
about serum zinc and relation to growth and maturation.  It 
found that decreased plasma s. zinc level is common in sickle 
cell disease (SS genotype) and is associated with decreased 
linear growth, skeletal and sexual maturation(75). 
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 The height for age and sexual maturity are found not to 
be related to serum zinc level in this study (P > 0.05) of both.  
This is similar to one study that failed to show an association 
between s. zinc concentrations and growth parameters(93).  
This results are also similar to the study conducted by Olivera 
et al(82), which found there is no difference in zinc level in 
children with SCA with or without growth failure, suggesting 
other metabolic disturbances are involves. 
 Plasma zinc may not be a sensitive indicator of growth-
limiting zinc deficiency, especially in patients with SCD for 
whom hemolyzed red blood cells may contaminate plasma 
samples. 
 A measurable effect on growth in  a controlled study is 
considered to indicate pre-existing growth-limiting zinc 
deficiency that has been at least partially corrected by 
provision of zinc supplements(67). 
 In the study done by Zamel BS and his colleagues about 
effect of zinc supplementation on growth and body 
composition in children with SCA(73,73) they found there were 
no differences in growth related to baseline plasma zinc 
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concentrations.  However, zinc supplementation was 
associated with greater linear growth and other indicators of 
nutritional status.  This finding suggest that the gradual 
growth failure in children with SCD-SS may be preventable 
with adequate nutritional care, particularly zinc 
supplementation. 
 Several factors may contribute to growth failure in SCA 
patients.  The study revealed that most patients are admitted 
frequently to hospital by febrile illnesses and painful crises, 
and significant number of them received blood transfusions 
several times in their course of illness indicating that 
chronicity and severity is a strong factor affecting their growth 
and maturity.  However diarrhoeal diseases are found to be 
irrelevant to their problem, because only 10% of them are 
admitted by diarrhoeal disease more than 5 times. 
 The nutritional history of patients included in the study 
was satisfactory (79% showed adequate nutritional history).  
Most of the families insist that they take sufficient amount of 
zinc containing food, like milk, meat and cereals, although 
most of them are of low socioeconomic classes (86%). 
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 However most studies of growth retarded children with 
SCA have shown adequate caloric and nutritional intake, 
indicating that growth failure can not be explained by 
nutritional factors alone in most patients(83). 
 The vaccination history of patients is excellent, because 
98.3% are completed their vaccination programme up to age 
and this because of availability of vaccines and probably 
repeated hospital admission may be a reason for completion of 
their vaccine programme. 
 Previous reports have linked zinc to growth abnormalities 
in children with SCD(75,76,87).  Relative to normal plasma zinc 
concentrations, low plasma zinc concentrations are associated 
with poorer growth status (i.e, a height for age z-score less 
than the 5th percentile) (89) a significantly lower height, weight, 
elbow breadth, upper arm muscle mass and delayed skeletal 
age(75). 
 The effect of zinc supplementation on prepuberal children 
with sickle cell disease has not been evaluated. 
CONCLUSION 
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1- Most of studied group children are from western 
tribes, of them a considerable number (68.3%) are a 
product of consanguious marriage. 
2- Patients are frequently admitted by febrile illnesses 
(mean 5.4.9) painful crises (mean = 4) and received 
blood transfusion (mean = 2.16), however diarrhea is 
not a common presentation among them (mean 1.26). 
3- Vaccination history is excellent, almost all of them are 
completed their vaccination (98.3%), taking their folic 
acid (98.3%), but only 17% of the 40% whom their 
age is 5 years or less are taking their prophylactic 
antibiotic. 
4- The commonest presentation is pallor, jaundice, fever 
and painful crises respectively, only minority are 
presented by oestomylities and CVA.  
5- Of their growth parameter, weight was found to be 
affected more (mean is -1.66) and was found to be 
related to low serum zinc level (P < 0.05).  The height 
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for age was less affected (mean height for age is – 
0.56) and was found to not related to zinc level. 
6- The sexual maturity is significantly delayed (75% had 
delayed Tanner stage for age, but found not to be 
related to their serum zinc level. 
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RECOMMENDATIONS 
 
 
- Screening of the families belonging to tribes with high 
incidence of sickle cell anaemia is important for early 
detection and proper management.  
- Health education is important to decrease the degree 
of consangious marriage, education about 
immunization prophylaxis, acute crises and 
comprehensive medical evaluation is mandatory for 
those patients. 
- The follow up of those patients should be by regular 
monitoring of growth parameters and nutritional 
assessment and control of acute crises, maintenance 
of hemoglobin level near normal; factors well known to 
affect their growth. 
- Although several studies fail to relative low s. zinc level 
with nutritional status in SCA patients, we can’t rule 
out any influence of malnutrition in the zinc results, 
so adequate nutritional intake particularly zinc may 
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improve growth, immunity and wound healing in those 
children. 
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